Kentucky Researchers Find MW150 Cuts Alcohol Withdrawal Inflammation in Animal and Cell Studies
Updated
Updated · Fox News · May 25
Kentucky Researchers Find MW150 Cuts Alcohol Withdrawal Inflammation in Animal and Cell Studies
1 articles · Updated · Fox News · May 25
University of Kentucky researchers reported that MW150, an experimental Alzheimer’s drug, reduced inflammatory markers tied to alcohol withdrawal in cell-culture and animal-model studies published in Alcohol.
The drug targets the brain inflammation pathway p38α MAPK, which scientists suspect helps drive relapse risk and long-term neurological damage in alcohol use disorder.
MW150 and related compound Neflamapimod are already in clinical testing for dementia and other neurodegenerative diseases, raising the possibility of faster repurposing if follow-up alcohol studies succeed.
Researchers cautioned the findings are still preclinical and need additional live-animal work to assess broader health effects, alcohol consumption changes and real-world withdrawal outcomes.
Outside experts said current detox medications mainly prevent dangerous withdrawal complications, leaving room for brain-health treatments that could help patients engage earlier in recovery.
A dementia drug may soon treat alcohol withdrawal. What does this surprising link reveal about our brains?
With dementia drugs and weight-loss shots now treating alcoholism, which breakthrough will redefine addiction recovery?
MW150 Shows Promise in Reducing Neuroinflammation During Alcohol Withdrawal: New Research Highlights Path to Human Trials
Overview
Researchers at the University of Kentucky’s Sanders-Brown Center on Aging have made a promising breakthrough in treating alcohol withdrawal. Their recent findings, published in May 2026, show that MW150—a drug first developed for neuroinflammation in dementia—can reduce brain inflammation linked to alcohol withdrawal. MW150 works by targeting and modulating the p38α MAPK pathway, a key mechanism in the brain’s inflammatory response. Initial studies in animal and cell models suggest that this approach could offer a new way to manage alcohol withdrawal by addressing its underlying inflammation, paving the way for future clinical research.